로딩 중…
지수 로딩 중…
Definium Therapeutics, Inc.
DFTX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$41.79-3.98%
2026-08-03
Financials
Valuation Metrics
Definium Therapeutics, Inc.'s Market Cap is $4.56B. At end of 2025 it was $1.20B. Ranked #1464 of 3,112 in US market (top 47%), #506 of 1,445 on NASDAQ (top 35%), #82 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.56B | US#1,464/3,112 Sec#82/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-238M | US—/3,112 Sec—/269 |
| Total Assets | $401M | US#2,826/3,112 Sec#185/269 |
| Net Assets | $279M | US#2,587/3,112 Sec#166/269 |
| Value | ||
| P/B | 16.35x | US#2,761/3,112 Sec#224/269 |
| FCF Yield | -3.15% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -85.19% | US#2,833/3,112 Sec#213/269 |
| ROA | -59.19% | US#2,996/3,112 Sec#234/269 |
| Financial Health | ||
| Debt Ratio | 43.91% | US#500/3,112 Sec#134/269 |
| Total Debt | $0.00 | US—/3,112 Sec—/269 |
| FCF | $-144M | US#2,673/3,112 Sec#186/269 |
| Cash | $263M | US#1,520/3,112 Sec#94/269 |
| Current Ratio | 4.69x | US#512/3,112 Sec#154/269 |
| Performance | ||
| 1Y Return | 395.14% | US#37/3,112 Sec#16/269 |
| 1M Return | -5.43% | US#2,279/3,112 Sec#128/269 |
| From 52W High | -15.06% | US#1,410/3,112 Sec#82/269 |
| 1Y MDD | -24.79% | US#1,021/3,112 Sec#56/269 |
| Trading | ||
| Volume | 1,864,220 shares | US#944/3,112 Sec#85/269 |
| Trading Value | $79M | US#1,057/3,112 Sec#63/269 |
| Per Share | ||
| EPS | $-2.06 | US—/3,112 Sec—/269 |
| BPS | $3.72 | US#2,340/3,112 Sec#149/269 |